Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
235 SEK | +2.17% | -3.29% | +10.85% |
Apr. 25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 51% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.01 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.85% | 513M | C+ | ||
-41.90% | 2.95B | C+ | ||
+19.36% | 1.88B | - | ||
-1.05% | 1.63B | - | ||
+33.96% | 1.34B | B+ | ||
-16.83% | 959M | - | ||
-21.96% | 888M | - | C- | |
+7.07% | 842M | - | ||
-26.98% | 623M | B+ | ||
-.--% | 489M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CEVI Stock
- Ratings CellaVision AB